Stockreport

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Catar...

Catalent, Inc.  (CTLT) 
Last catalent, inc. earnings: 2/3 07:30 am Check Earnings Report
US:NYSE Investor Relations: investor.catalent.com
PDF Proportion of Patients Requiring Rescue Sedation Was Nearly Two-Fold Higher for Sublingual Midazolam Compared with MELT-300 (P=0.003) MELT-300 Had a Favorable Safety [Read more]